Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
钠-葡萄糖协同转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂联合治疗的心脏保护作用。
批准号：
404134
负责人：
Zarrin Khat Dorrin
金额：
$7.65万
依托单位：
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-10-01 至 2021-10-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Heart disease remains a leading cause of death and disability, and heart attack due to blockages in the heart's major arteries remains the dominant mechanism. Optimal treatment requires rapid relief from such blockages, and thus restoring blood flow to mi
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cardioprotective benefits of combination treatment with a sodium-glucose co-transporter-2 inhibitor and a glucagon-like peptide-1 receptor agonist.
-
批准号：396625
-
项目类别：Studentship Programs
-
资助金额：$10.93万
-
财政年份：2018
-
负责人：Zarrin Khat Dorrin
-
依托单位：
Cardioprotective Effects of Dapagliflozin and Exenatide
-
批准号：367395
-
项目类别：Studentship Programs
-
资助金额：$1.27万
-
财政年份：2016
-
负责人：Zarrin Khat Dorrin
-
依托单位：
海外基金
